Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label MPC-7869 (Flurizan) in Alzheimer's Disease
NCT00380276Phase 3Terminated
- Sponsor
- Myrexis, Inc.
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of tarenflurbil in Alzheimer's disease (AD), sponsored by Myrexis, Inc.. Started Sep 2006; status: terminated.
02
Drugs
tarenflurbil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00380276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380276.